Related Experiment Video
Updated: May 6, 2026
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
Published on: June 12, 2021
Evaluation of cancer immunity in mice
Mary L Disis1, Karolina Palucka
1Tumor Vaccine Group, Center for Translational Medicine in Women's Health, University of Washington, Seattle, Washington 98109;
Abstract:
There have been significant advances in the development and application of novel therapeutic approaches and improved diagnostics for cancer in the past decade. Manipulation and/or assessment of cancer-specific immunity have been central to these advances. Murine models are a standard for the preclinical development of cancer immunotherapeutics. However, critical advances in our understanding of the role of the immune microenvironment and the assessment of cancer-specific immunity have not been fully applied to rodent models. Methods to preserve the function of immune cells after cryopreservation and standard approaches to quantitative immune assays have not been developed. Furthermore, a detailed evaluation of the immune tumor environment, which can impact a clinical response to different agents, is rarely undertaken as models are being contemplated. Rapid translation of immunoncology agents to the clinic will require standardization of immunologic assay methods and a more detailed immunologic characterization of common mouse models. Outlined here are the critical elements in assessing immunity in cancer mouse models and suggestions concerning the standardization of approaches when using these models for the study of immunoncology.
Insights
Standardizing immune assays and characterizing mouse models are crucial for advancing cancer immunotherapy research. This ensures reliable preclinical data for developing novel cancer treatments and translating them to clinical applications.
Area of Science:
- Immunology
- Oncology
- Preclinical Research
Background:
- Cancer immunotherapy has seen significant advances, driven by cancer-specific immunity.
- Murine models are standard for preclinical cancer immunotherapeutic development.
- Current rodent models lack comprehensive immune microenvironment assessment and standardized immune assays.
Purpose of the Study:
- To highlight critical elements for assessing immunity in cancer mouse models.
- To suggest standardization of immunologic assay methods for preclinical studies.
- To improve the translation of immuno-oncology agents to clinical settings.
Main Methods:
- Review of current practices in assessing cancer immunity in murine models.
- Identification of gaps in immune cell preservation and quantitative assay development.
- Emphasis on detailed immunologic characterization of tumor microenvironments.
Main Results:
- Standardized methods for immune cell cryopreservation and quantitative assays are lacking.
- Detailed evaluation of the tumor immune microenvironment is rarely performed in preclinical models.
- Current approaches do not fully leverage advances in understanding cancer immunity.
Conclusions:
- Standardization of immunologic assay methods is essential for reliable preclinical data.
- Comprehensive immunologic characterization of mouse models is needed.
- Improved preclinical models will accelerate the translation of cancer immunotherapies.
